N/A-testing NOT APPLICABLE to organism. CZOL-cefazolin, CTRX-ceftriaxone, CTAZ-ceftazidime, CFPM-cefepime, GEN-gentamicin, TOB-tobramycin, T/S-trimethoprim/sulfamethoxazole, CIP-ciprofloxacin, MER-meropenem, P/T-piperacillin-tazobactam
Values are % of strains testing susceptible to listed antibiotic. Unless indicated, results are for all inpatient/ED locations and culture sites.
Susceptibilities are based on data from 2019-2021. Isolate numbers and 95% confidence intervals are provided to gauge precision of susceptibility estimate.
| Organism | Total Isolates* |
CZOL %S (95% CI) |
CTRX %S (95% CI) |
CTAZ %S (95% CI) |
CFPM %S (95% CI) |
GEN %S (95% CI) |
TOB %S (95% CI) |
T/S %S (95% CI) |
CIP %S (95% CI) |
P/T %S (95% CI) |
MER %S (95% CI) |
|
Enterobacter cloacae |
83 |
N/A |
N/A |
N/A |
89 (98)# (80,94) |
100 (96,100) |
98 (93,100) |
93 (87,97) |
93 (87,97) |
75 (66,84) |
98 (93,100) |
|
Escherichia coli |
292 |
60** (55,67) |
86 (82,90) |
91 (88,94) |
91 (94)# (88,94) |
90 (87,94) |
92 (88,95) |
64 (59,70) |
78 (74,83) |
97 (95,99) |
100 (98,100) |
|
Klebsiella oxytoca |
53 |
18** (10,32) |
88 (77,95) |
98 (90,100) |
96 (87,99) |
96 (87,99) |
96 (87,99) |
90 (80,96) |
94 (85,98) |
86 (74,93) |
100 (92,100) |
|
Klebsiella pneumoniae |
100 |
66** (56,75) |
90 (83,94) |
91 (84,95) |
93 (86,97) |
93 (86,97) |
96 (90,98) |
76 (67,83) |
82 (73,88) |
95 (89,98) |
100 (96,100) |
| Pseudomonas aeruginosa | 100*** | N/A | N/A |
89 (82,94) |
93 (86,97) |
N/A |
96 (90,98) |
N/A |
88 (80,93) |
90 (83,94) |
94 (88,97) |
|
Serratia marcescens |
38 |
N/A |
97 (87,100) |
97 (87,100) |
97 (97)# |
97 (87,100) |
97 (87,100) |
100 (91,100) |
94 |
97 (87,100) |
100 (90,100) |
*When fewer than 30 isolates are reported, % susceptible may not reflect robust estimate of population susceptibility
**Reporting of Cefazolin susceptibility for E. coli, Klebsiella spp and Proteus is based on breakpoints for complicated infections - see outpatient E. coli susceptibilities for reporting based on uncomplicated UTI breakpoints
***Pseudomonas aeruginosa isolates do not include isolates from patients with cystic fibrosis.
# Number in parentheses represents the percentage of isolates both fully susceptible and susceptible-dose dependent to cefepime, for each organism. Susceptible-dose dependent isolates of Enterobacteriaceae are those with MIC 4 to 8 micrograms/mL for a cefepime dose of 50 mg/kg/dose iv q8h with maximum 2g/dose, as routinely recommended per BCH Pediatric Antimicrobial Dosing Guidelines, is anticipated to be active.